News for Design Therapeutics, Inc. (DSGN)

Design Therapeutics (DSGN) has commenced its open-label Phase 1/2 RESTORE-FA clinical trial with the initial dosing of a Friedreich ataxia (FA) patient using DT

Design Therapeutics (DSGN) initiated dosing of Friedreich ataxia patients in Australia in its RESTORE-FA Phase 1/2 trial. FDA has placed a clinical hold

Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to

**media[618062]**

Design Therapeutics (DSGN) has unveiled encouraging results from its Phase 1 trial of DT-168, a therapy under investigation for eye conditions. The trial's find

Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Design Therapeut

**media[600835]**

Design Therapeutics (DSGN) has appointed Dr. Chris Storgard as its new Chief Medical Officer. Dr. Storgard brings a wealth of experience from his recent role at

CARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. ( DSGN), a clinical-stage biotechnology company developing treatments for serio

SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering

**media[597926]**

Design Therapeutics (DSGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The consensus price target hints at a 31.3% upside potential for Design Therapeutics (DSGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025 Dosing Complete in

CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. ( DSGN), a clinical-stage biotechnology company developing treatments for serio

Utah-based Sintx Technologies, Inc. (SINT) is up over 87 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Shares of Global Blue Group Holding AG GB rose sharply during Wednesday's pre-market trading session after the company announced it will be acquired by Shift4 f...

Shares of GCL Global Holdings Ltd GCL rose sharply in today’s pre-market trading. GCL and RF Acquisition Corp. disclosed the successful completion of their b...

Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results in Friedreich's ataxia. See more here.